Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orelabrutinib Consolidation and Maintenance in Treatment-Naïve MZL
NCT07372365Phase 2Recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Oct 2025
- Primary completion
- Apr 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of orelabrutinib in marginal zone lymphoma (MZL), sponsored by First Affiliated Hospital of Soochow University. Started Oct 2025; status: recruiting.
02
Drugs
orelabrutinib
03
Conditions
marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT07372365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07372365.